Navigation Links
Genta Receives Key Patent Related to Oral Gallium Compound G4544
Date:4/14/2008

. Ganite is exclusively marketed in the U.S. by Genta and is available to patients outside the U.S. on a "named-patient" basis.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi- synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory app
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Genta Incorporated Announces Third Quarter 2007 Financial Results
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Clinical Programs Featured at American Society of Hematology Meeting
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  Depomed, Inc. (NASDAQ: DEPO ) ... Board of Directors, after careful consideration and with ... advisors, has unanimously rejected the purported revised, highly ... plc (NASDAQ: HZNP ) ("Horizon") to acquire ... an all-stock transaction (the "July 21 Proposal"). ...
(Date:7/29/2015)... 2015 The U.S. Food and Drug Administration ... ReShape Integrated Dual Balloon System, that may help fill ... with obesity and one or more obesity-related conditions, according ... (ASMBS), the nation,s largest organization for bariatric surgeons. ... review the FDA has approved this new device for ...
(Date:7/29/2015)... 29, 2015  Shareholder rights law firm Robbins ... officers and directors of AMAG Pharmaceuticals, Inc. (NASDAQGS: ... Pharmaceuticals operates as a specialty pharmaceutical company that ... care.  The company markets Makena, a hydroxyprogesterone caproate ... in women with a singleton pregnancy. ...
Breaking Medicine Technology:Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 2Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 3Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 4Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 5Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 6Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 7Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 8Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plc 9American Society for Metabolic and Bariatric Surgery Views New Balloon Device For Obesity As Bridge Between Medications And Bariatric Surgery 2American Society for Metabolic and Bariatric Surgery Views New Balloon Device For Obesity As Bridge Between Medications And Bariatric Surgery 3Robbins Arroyo LLP Is Investigating the Officers and Directors of AMAG Pharmaceuticals, Inc. (AMAG) on Behalf of Shareholders 2
... Sept. 22, 2011 Biodel Inc. (Nasdaq: BIOD ... Chief Executive Officer, will be presenting at the 6th Annual ... New York.  The presentation is scheduled for Tuesday, September 27, ... to the live webcast or a replay of the presentation, ...
... Sept. 22, 2011 Reportlinker.com announces that ... in its catalogue: Generic ... http://www.reportlinker.com/p0619265/Generic-Drugs-The-Global-Market--Focus-on-Europe.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment ... * An examination of the strategies employed ...
Cached Medicine Technology:Generic Drugs: The Global Market--Focus on Europe 2Generic Drugs: The Global Market--Focus on Europe 3Generic Drugs: The Global Market--Focus on Europe 4Generic Drugs: The Global Market--Focus on Europe 5Generic Drugs: The Global Market--Focus on Europe 6Generic Drugs: The Global Market--Focus on Europe 7Generic Drugs: The Global Market--Focus on Europe 8Generic Drugs: The Global Market--Focus on Europe 9Generic Drugs: The Global Market--Focus on Europe 10
(Date:7/30/2015)... ... 2015 , ... Summer is the dry eye season, especially in parts of ... dry and hot 2015 summer season and the dry eye rate in the hot ... discuss the 2015 summer season and identify the primary dry eye hot spots on ...
(Date:7/30/2015)... ... July 30, 2015 , ... According to Chicago Implant ... a complete removable denture acceptable. The demand for dental implants is rising exponentially ... expensive, immediate loading techniques will have the ability to offer the patient a ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... contract manufacturing and packaging services for consumer brands, recently completed a consolidation of ... Baltimore, MD. Previously, the company operated out of two separate locations situated 11 ...
(Date:7/30/2015)... ... 2015 , ... Addictions Training Institute has announced the launch of ... and Substance Abuse Counselors. , "We are thrilled to be launching Addictions Training Institute,” ... of Alcohol and Drug Counselors nationwide. We are excited to be helping fill ...
(Date:7/29/2015)... (PRWEB) , ... July 30, 2015 , ... ... available for their clients, BOC approved provider of online continuing education courses ... course offerings to their exclusive Andrews Research and Education Sports Medicine Series. , ...
Breaking Medicine News(10 mins):Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 3Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 3Health News:Addictions Training Institute Announces New Online Certificate Program for Alcohol and Drug Counselors 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 3
... de Montréal and the Centre hospitalier de l’Université de ... the// human immunodeficiency virus (HIV). For the first time, ... to HIV and found a way to correct the ... biology, immunology, and virology, has confirmed the identification of ...
... epidemic proportions in Gujarat according to the government there ... any part of flood-ravaged Surat.// ,Quoting the ... State Health Secretary Amarjit Singh, Delhi, said that all ... rodent samples for plague as well as for Hantavirus ...
... emotional debate, US health authorities have approved the sale ... women 18 years and older.// ,But girls ... the Food and Drug Administration said Thursday. ... contained in birth control pills, interrupts pregnancy if used ...
... Scientists at the Indian Council of Agricultural Research (ICAR) have ... for diabetics because of its low caloric// content. ... blood can be developed from this new 'Dicoccum' variety of ... the Dharwad center of University of Agricultural Sciences developed the ...
... compound called rasfonin has been synthesized from a fungus for ... a New Zealand cave cave. //A chemical found in this ... harming healthy cells. ,"In 2000, scientists in Japan ... a prototype anticancer agent, but no one has been able ...
... in the center of attention now a days experts have ... actually be too fat //for their own good. ... coming from several top health groups, like the World Health ... the American Academy of Pediatrics as to if baby fat, ...
Cached Medicine News:Health News:Researchers Make a Major Strategic Breakthrough in Controlling the AIDS Virus 2Health News:Cancer-Killing Compound From A Fungus 2Health News:Chubbiness In Babies Might Not Be A Cute Sign 2